Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Bernstein: bitcoin price could bottom out if Trump wins

Bernstein: bitcoin price could bottom out if Trump wins

Bitget2024/08/19 15:12

A new report from Bernstein Research suggests that the cryptocurrency market, particularly Bitcoin, could undergo a major shift based on the outcome of the upcoming U.S. presidential election. The analysis suggests that a potential victory for Donald Trump could catalyze a bottoming in the price of Bitcoin, which could lead to an increase in the price of major cryptocurrencies. The report states, “We believe that Bitcoin prices will only bottom if the crypto market becomes interested in a potential Trump victory, as the crypto market continues to interpret a Republican victory as favorable for crypto policy.” This insight comes at a time when cryptocurrency prices remain range-bound, which Bernstein attributes to the uncertainty surrounding the U.S. election.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds